Quantum Biopharma (QNTM) Asset Writedowns and Impairment (2020 - 2023)
Quantum Biopharma recorded quarterly Asset Writedowns and Impairment of $480096.0 in Q1 2023, up 2062.32% quarter-over-quarter from $22202.8 in Q3 2020.
Quantum Biopharma's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $480096.0 for Q1 2023.
- In Q1 2023, Asset Writedowns and Impairment changed N/A year-over-year to $480096.0; the TTM figure through Dec 2024 stood at $480096.0 (changed N/A YoY), while the FY2023 annual figure was $4.6 million, changed N/A from the prior year.
- Asset Writedowns and Impairment came in at $480096.0 for Q1 2023 at Quantum Biopharma, up from $22202.8 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $480096.0 in Q1 2023 to a low of $22202.8 in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 480,096.00 |
| Mar 31, 2023 | 480,096.00 |
| Sep 30, 2020 | 22,202.79 |
| Sep 30, 2020 | 22,202.79 |
| Mar 31, 2020 | 67,026.09 |
| Mar 31, 2020 | 67,026.09 |